Program
Bilpatide
Also written as “RAY1225” and “14C-RAY1225”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Renal Insufficiency, led by Guangdong Zhongsheng Pharmaceutical.
Furthest: phase 3, since Mar 18, 202512 company-led studies, 8 open or runningNext primary completion: Dec 1, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guangdong Zhongsheng Pharmaceutical | 128 open or running | phase 3since Mar 18, 2025 | Apr 11, 2023 | Dec 1, 2026phase 3 · NCT07139535 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 11, 2023First study: phase 1 study in ObesityFirst studyNCT05835752 · 68 enrolled · China
- Feb 3, 20242 phase 2 studiesNCT06254274, NCT06254261
- Aug 27, 20242 phase 1 studiesNCT06577428, NCT06577415
- Sep 23, 2024Phase 1 study in Renal InsufficiencyNCT06613763 · 32 enrolled · China
- Mar 18, 2025Phase 3 study in ObesityNCT06893016 · 640 planned · China
- Aug 11, 20252 phase 3 studies in T2DMNCT07139548, NCT07139535
- Jan 14, 2026Phase 1 study in ObesityNCT07362030 · 32 enrolled · China
- Feb 27, 2026Phase 1 study in Basic ScienceNCT07460284 · 8 planned · China
- Sep 14, 2026Phase 1 study in Basic ScienceNCT07827027 · 68 planned
Ahead
- Nov 5, 2026Primary completion: phase 1 study in Basic ScienceNCT07827027
- Dec 1, 2026Primary completion: phase 3 study in T2DMNCT07139548
- Dec 1, 2026Primary completion: phase 3 study in T2DMNCT07139535
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07827027Basic Science | 1 | Not yet recruiting | Nov 5, 2026 | 68 |
| NCT07460284Basic Science · China | 1 | Not yet recruiting | Oct 14, 2026 | 8 |
| NCT07362030Obesity · China | 1 | Active, not recruiting | Dec 27, 2025 | 32 |
| NCT07139548T2DM · China | 3 | Not yet recruiting | Dec 1, 2026 | 600 |
| NCT07139535T2DM · China | 3 | Not yet recruiting | Dec 1, 2026 | 350 |
| NCT06893016Obesity · China | 3 | Recruiting | Jun 15, 2026 | 640 |
| NCT06613763Renal Insufficiency · China | 1 | Completed | Jan 10, 2025 | 32 |
| NCT06577428Healthy · China | 1 | Completed | Sep 29, 2024 | 48 |
| NCT06577415Hepatic Impairment · China | 1 | Recruiting | Oct 31, 2025 | 24 |
| NCT06254274Diabetes Mellitus, Type 2 · China | 2 | Completed | Jul 20, 2025 | 210 |
| NCT06254261Obesity · China | 2 | Recruiting | Dec 20, 2025 | 270 |
| NCT05835752Obesity · China | 1 | Completed | Mar 1, 2024 | 68 |
How it is read
Names in the registry
- “RAY1225”, 13 entries
- “14C-RAY1225”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 4 studies
- Diabetes Mellitus, Type 2, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.